Clinical Trials on Adult Nodular Sclerosis Hodgkin Lymphoma

Total 5606 results

National Cancer Institute (NCI)

Completed

Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy

Recurrent Adult Hodgkin Lymphoma | Stage III Adult Hodgkin Lymphoma | Stage IV Adult Hodgkin Lymphoma | Recurrent/Refractory Childhood Hodgkin Lymphoma | Stage III Childhood Hodgkin Lymphoma | Stage IV Childhood Hodgkin Lymphoma | Stage I Adult Hodgkin Lymphoma | Stage I Childhood Hodgkin Lymphoma | Stage II Adult Hodgkin Lymphoma and other conditions

United States
National Cancer Institute (NCI)

Completed

Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma

Recurrent Adult Hodgkin Lymphoma | Adult Lymphocyte Depletion Hodgkin Lymphoma | Adult Lymphocyte Predominant Hodgkin Lymphoma | Adult Mixed Cellularity Hodgkin Lymphoma | Adult Nodular Sclerosis Hodgkin Lymphoma | Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma | Adult Favorable Prognosis... and other conditions

United States
Beth Christian

Completed

Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Recurrent Adult Hodgkin Lymphoma | Adult Lymphocyte Depletion Hodgkin Lymphoma | Adult Lymphocyte Predominant Hodgkin Lymphoma | Adult Mixed Cellularity Hodgkin Lymphoma | Adult Nodular Sclerosis Hodgkin Lymphoma | Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma

United States
Ohio State University Comprehensive Cancer Center
Novartis; Celgene

Completed

A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma

Recurrent Adult Hodgkin Lymphoma | Adult Lymphocyte Depletion Hodgkin Lymphoma | Adult Lymphocyte Predominant Hodgkin Lymphoma | Adult Mixed Cellularity Hodgkin Lymphoma | Adult Nodular Sclerosis Hodgkin Lymphoma | Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma

United States
Northwestern University
Seagen Inc.; Robert H. Lurie Cancer Center

Unknown

Brentuximab Vedotin and Combination Chemotherapy in Treating Older Patients With Previously Untreated Stage II-IV Hodgkin Lymphoma

Stage III Adult Hodgkin Lymphoma | Stage IV Adult Hodgkin Lymphoma | Stage II Adult Hodgkin Lymphoma | Adult Lymphocyte Depletion Hodgkin Lymphoma | Adult Lymphocyte Predominant Hodgkin Lymphoma | Adult Mixed Cellularity Hodgkin Lymphoma | Adult Nodular Sclerosis Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Completed

SGN-30 and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Recurrent Adult Hodgkin Lymphoma | Adult Lymphocyte Depletion Hodgkin Lymphoma | Adult Lymphocyte Predominant Hodgkin Lymphoma | Adult Mixed Cellularity Hodgkin Lymphoma | Adult Nodular Sclerosis Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Completed

Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

Recurrent Adult Hodgkin Lymphoma | Adult Lymphocyte Depletion Hodgkin Lymphoma | Adult Mixed Cellularity Hodgkin Lymphoma | Adult Nodular Sclerosis Hodgkin Lymphoma

United States
Northwestern University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Active, not recruiting

Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Lymphocyte-Rich Classical Hodgkin Lymphoma | Recurrent Lymphocyte-Depleted Classical Hodgkin Lymphoma | Recurrent Mixed Cellularity Classical Hodgkin Lymphoma | Recurrent Nodular Sclerosis Classical Hodgkin Lymphoma | Refractory Lymphocyte-Depleted Classical Hodgkin Lymphoma | Refractory Mixed... and other conditions

United States
Marker Therapeutics, Inc.

Recruiting

Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma (APOLLO)

Hodgkin Lymphoma | Non Hodgkin Lymphoma | Hodgkin Lymphoma, Adult | Non-Hodgkin Lymphoma, Adult | Non-Hodgkin Lymphoma, Refractory | Non-Hodgkin Lymphoma, Relapsed | Hodgkin's Lymphoma, Relapsed, Adult

United States
Estrella Biopharma, Inc.
Eureka Therapeutics Inc.

Not yet recruiting

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL) (Starlight-1)

Lymphoma | Lymphoma, Non-Hodgkin | Non-Hodgkin's Lymphoma | Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | High-grade B-cell Lymphoma | CNS Lymphoma | Lymphomas Non-Hodgkin's B-Cell | Relapsed Non-Hodgkin Lymphoma | Lymphoma, Non-Hodgkins | Large B-Cell Lymphoma and other conditions
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

CPI-613 and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma

Peripheral T-cell Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Adult Nasal Type Extranodal NK/T-cell Lymphoma | Hepatosplenic T-cell Lymphoma | Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Adult Hodgkin Lymphoma | Recurrent Adult T-cell Leukemia/Lymphoma and other conditions

United States
Tomsk National Research Medical Center of the Russian...
Uppsala University

Completed

Molecular Imaging of Lymphoma Using Labeled Technetium-99m 1-Thio-D-Glucose

Hodgkin Lymphoma, Adult | Non-Hodgkin Lymphoma, Adult

Russian Federation
National Cancer Institute (NCI)

Active, not recruiting

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

Ann Arbor Stage III Hodgkin Lymphoma | Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma | Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma | Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma | Ann Arbor Stage IV Hodgkin Lymphoma | Ann Arbor Stage IV... and other conditions

United States, Canada, Puerto Rico
Grupo Argentino de Tratamiento de la Leucemia Aguda
Takeda

Recruiting

RWE of Brentuximab Vedotin Consolidation in Patients With RR HL Who Receive Salvage Chemotherapy and ASCT

Refractory Hodgkin Lymphoma | Hodgkin Lymphoma, Adult | Relapsed Hodgkin's Disease, Adult

Argentina
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Chemotherapy With or Without Additional Chemotherapy and/or Radiation Therapy in Treating Children With Newly Diagnosed Hodgkin's Disease

Stage III Childhood Hodgkin Lymphoma | Stage IV Childhood Hodgkin Lymphoma | Stage I Childhood Hodgkin Lymphoma | Stage II Childhood Hodgkin Lymphoma | Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma | Childhood Lymphocyte-Depleted Classical Hodgkin Lymphoma | Childhood Mixed Cellularity... and other conditions

United States, Canada, Australia, New Zealand, Puerto Rico, Switzerland, Israel
GlyPharma Therapeutics
VectivBio AG

Withdrawn

Safety, Tolerability, PK/PD of FE 203799 in Adults With Lymphomas

Lymphoma, Non-Hodgkin's, Adult | Lymphoma, Hodgkin's, Adult
University of Cologne

Completed

Ibrutinib in Relapsed Nodular Lymphocyte-predominant Hodgkin Lymphoma (NLPHL) (IRENO)

Nodular Lymphocyte-Predominant Hodgkin's Lymphoma

Germany
Fred Hutchinson Cancer Center
National Cancer Institute (NCI); National Heart, Lung, and Blood Institute...

Withdrawn

HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection

Stage III Adult Hodgkin Lymphoma | Stage IV Adult Hodgkin Lymphoma | Human Immunodeficiency Virus 1 Positive | Stage I Adult Hodgkin Lymphoma | Stage II Adult Hodgkin Lymphoma | Stage I Adult Non-Hodgkin Lymphoma | Stage II Adult Non-Hodgkin Lymphoma | Stage III Adult Non-Hodgkin Lymphoma | Stage IV...

United States
Mayo Clinic

Withdrawn

Lopinavir and Ritonavir in Improving Immune Response to Vaccines in Patients With Complete Remission Following A Bone Marrow Transplant for Hodgkin Lymphoma

Hodgkin Lymphoma | Stage III Adult Hodgkin Lymphoma | Stage IV Adult Hodgkin Lymphoma | Stage I Adult Hodgkin Lymphoma | Stage II Adult Hodgkin Lymphoma

United States
John Reneau

Recruiting

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Recurrent Adult T-Cell Leukemia/Lymphoma | Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Refractory Adult T-Cell Leukemia/Lymphoma

United States
Northwestern University
National Cancer Institute (NCI); Merck Sharp & Dohme LLC

Active, not recruiting

PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin Lymphoma

Classical Hodgkin Lymphoma | Lymphocyte-Depleted Classical Hodgkin Lymphoma | Lymphocyte-Rich Classical Hodgkin Lymphoma | Mixed Cellularity Classical Hodgkin Lymphoma | Nodular Sclerosis Classical Hodgkin Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma

Classic Hodgkin Lymphoma | Lymphocyte-Rich Classic Hodgkin Lymphoma | Ann Arbor Stage IB Hodgkin Lymphoma | Ann Arbor Stage II Hodgkin Lymphoma | Ann Arbor Stage IIA Hodgkin Lymphoma | Ann Arbor Stage IIB Hodgkin Lymphoma | Ann Arbor Stage I Hodgkin Lymphoma | Ann Arbor Stage I Mixed Cellularity... and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Lymphoma

Stage I Childhood Hodgkin Lymphoma | Stage II Childhood Hodgkin Lymphoma | Childhood Lymphocyte Depletion Hodgkin Lymphoma | Childhood Mixed Cellularity Hodgkin Lymphoma | Childhood Nodular Sclerosis Hodgkin Lymphoma | Childhood Favorable Prognosis Hodgkin Lymphoma

United States
National Cancer Institute (NCI)

Terminated

Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma

Stage I Multiple Myeloma | Stage II Multiple Myeloma | Stage III Multiple Myeloma | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent... and other conditions

United States
National Cancer Institute (NCI)

Completed

Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Splenic Marginal Zone Lymphoma | Anaplastic Large Cell Lymphoma | Recurrent Adult Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent... and other conditions

United States
Baylor College of Medicine
Center for Cell and Gene Therapy, Baylor College of Medicine

Recruiting

(TAA)-Specific Cytotoxic T-Lymphocytes to Pediatric Patients With Lymphomas (pediTACTAL). (pediTACTAL)

Hodgkins Lymphoma | Non Hodgkins Lymphoma

United States
University Hospital, Brest

Completed

Interest of a Systematic One-year Monitoring by 18F-FDG PET-CT (LYMPHOTEP1)

Diagnostic Imaging | Relapsed Non Hodgkin Lymphoma | Relapsed Hodgkin's Disease, Adult | Malignant Lymphoma
Spectrum Pharmaceuticals, Inc

Completed

Study of Vinorelbine Liposomes Injection for Advanced Solid Tumors, Non-Hodgkin's Lymphoma or Hodgkin's Disease

Non-Hodgkins Lymphoma | Tumors | Hodgkins Disease

United States, Canada
Cellect Biotechnology

Unknown

Non-interventional, Long-term Follow-up of Subjects Who Completed ApoGraft-01 Study

Acute Lymphoblastic Leukemia (ALL) | Hodgkin Lymphoma, Adult | Acute Myelogenous Leukemia (AML) | Non Hodgkin Lymphoma (NHL)

Israel
National Cancer Institute (NCI)

Recruiting

Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma

Nodular Lymphocyte Predominant B-Cell Lymphoma | Recurrent Nodular Lymphocyte Predominant B-Cell Lymphoma | Refractory Nodular Lymphocyte Predominant B-Cell Lymphoma

United States
Rambam Health Care Campus

Completed

Risk Adapted Beacopp Regimen for Standard and High Risk Hodgkin Lymphoma

Classical Hodgkin Lymphoma | Nodular Sclerosis | Mixed Cellularity | Lymphocyte Depletion | Lymphocyte Rich

Israel
Hospital Regional de Alta Especialidad del Bajio
Universidad de Guanajuato

Recruiting

Treatment Strategy for Relapsed/Refractory Hodgkin Lymphoma

Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Relapsed Hodgkin's Disease, Adult

Mexico
Dana-Farber Cancer Institute
Bristol-Myers Squibb

Active, not recruiting

Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL

Hodgkin Lymphoma | Refractory Hodgkin Lymphoma | Relapsed Hodgkin's Disease, Adult

United States
Incyte Corporation

Terminated

INCB040093 and INCB040093 Combined With Itacitinib (INCB039110) in Relapsed/Refractory Hodgkin Lymphoma

Refractory Hodgkin Lymphoma | Recurrent Adult Hodgkin's Lymphoma
National Cancer Institute (NCI)

Terminated

Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
Tessa Therapeutics

Active, not recruiting

Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT)

Hodgkin Lymphoma, Adult | Hodgkin Disease Recurrent | Hodgkin Disease Refractory | Hodgkin Disease, Pediatric

United States
National Cancer Institute (NCI)

Terminated

CCI-779 in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Hodgkin Lymphoma | Refractory Chronic Lymphocytic Leukemia

United States
University of Giessen

Completed

Bendamustine Plus Rituximab Versus CHOP Plus Rituximab

Marginal Zone Lymphomas | Non-Hodgkin Lymphomas | Follicular Lymphomas | Immunocytomas | Lymphocytic Lymphomas

Germany
Hebei Senlang Biotechnology Inc., Ltd.

Recruiting

CAR-T Cells in Treating Patients With Relapsed or Refractory NHL

Refractory Indolent Adult Non-Hodgkin Lymphoma

China
Reid Merryman, MD
AbbVie; Genmab

Recruiting

Epcoritamab and Rituximab for First-line Follicular Lymphoma

Follicular Lymphoma | Low Grade Non-Hodgkin's Lymphoma, Adult

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Terminated

Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease (ANGELA)

Hodgkin Disease | Non-Hodgkins Lymphoma

United States
Baylor College of Medicine
The Methodist Hospital Research Institute; Center for Cell and Gene Therapy...

Recruiting

CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)

Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed Non Hodgkin Lymphoma | Relapsed Adult ALL | Relapsed CLL | Refractory B-Cell Small Lymphocytic Lymphoma

United States
National Cancer Institute (NCI)

Completed

Alisertib in Treating Patients With Relapsed or Refractory Peripheral T-Cell Non-Hodgkin Lymphoma

Anaplastic Large Cell Lymphoma | Recurrent Adult Non-Hodgkin Lymphoma | Angioimmunoblastic T-Cell Lymphoma | Hepatosplenic T-Cell Lymphoma | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma | Recurrent Adult T-Cell Leukemia/Lymphoma | Adult Nasal Type Extranodal NK/T-Cell Lymphoma

United States, Canada
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma

Ann Arbor Stage I Grade 1 Follicular Lymphoma | Ann Arbor Stage I Grade 2 Follicular Lymphoma | Ann Arbor Stage II Grade 1 Follicular Lymphoma | Ann Arbor Stage II Grade 2 Follicular Lymphoma | Ann Arbor Stage IV B-Cell Non-Hodgkin Lymphoma | Ann Arbor Stage I B-Cell Non-Hodgkin Lymphoma | Ann... and other conditions

United States
PrECOG, LLC.
Genentech, Inc.

Completed

Phase II Venetoclax, Obinutuzumab and Bendamustine in High Tumor Burden Follicular Lymphoma as Front Line Therapy (PrE0403)

Follicular Lymphoma | Non-Hodgkin's Lymphoma Follicular | Non-Hodgkin's Lymphoma, Adult High Grade

United States
Stanford University
National Institutes of Health (NIH); Amgen

Completed

Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma Patients Receiving Antibody Treatment

Lymphoma, Non-Hodgkin | Lymphomas: Non-Hodgkin | Lymphomas: Non-Hodgkin Peripheral T-Cell | Lymphomas: Non-Hodgkin Cutaneous Lymphoma | Lymphomas: Non-Hodgkin Diffuse Large B-Cell | Lymphomas: Non-Hodgkin Follicular / Indolent B-Cell | Lymphomas: Non-Hodgkin Mantle Cell | Lymphomas: Non-Hodgkin Marginal... and other conditions

United States
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Collecting and Storing Samples of Bone Marrow and Blood From Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma

Recurrent Adult Acute Lymphoblastic Leukemia | Recurrent Adult Non-Hodgkin Lymphoma | Recurrent Childhood Acute Lymphoblastic Leukemia | Recurrent Childhood Non-Hodgkin Lymphoma

United States, Canada, Puerto Rico, Australia, Switzerland
Baylor College of Medicine
The Methodist Hospital Research Institute

Terminated

Lmp1 and Lmp2 Specific CTLs Following Cd45 Antibody for Relapsed Ebv-Positive Hodgkin's Or Non-Hodgkin's Lymphoma (ALDI)

Non-Hodgkin Lymphoma | Hodgkins Lymphoma

United States
National Cancer Institute (NCI)

Completed

PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma and other conditions

United States
St. Jude Children's Research Hospital

Recruiting

Patient-Reported Outcomes and Quality of Life in Adult and Pediatric Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma (NLPHL)

Nodular Lymphocyte-Predominant Hodgkin Lymphoma

United States

Clinical Trials on Adult Nodular Sclerosis Hodgkin Lymphoma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Iran

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations